Life Sciences



Meet the Co-chairs - TAGLAW


Rummel, Barbara Lano
Lindquist & Vennum (Minnesota)
brummel@lindquist.com


Tauber, Paul J.
Coblentz, Patch, Duffy & Bass LLP
ptauber@coblentzlaw.com



Kvale's Life Sciences Team has issued a new newsletter with important healthcare and life sciences updates in Norway. 

Included in the newsletter: 

  1. Branded vs. generic prescription
  2. The pediatric regulation will be implemented in Norwegian law as from 1 September 2017. The pharmaceutical industry can apply for a patent extension from 1 August.
  3. Medical Devices – The supervision of medical equipment will be transferred to the Norwegian Medicines Agency
  4. New maximum and minimum limits for Food Supplements

Click here to read the newsletter.


Contact: Rainer Herzig; Preslmayr Rechtsanwälte (Austria)

Introduction

Article 13(1) of the EU Supplementary Protection Certificate (SPC) Regulation (469/2009)(1) provides that an SPC will take effect at the end of the lawful term of a basic patent for a period equal to that which elapsed between the date on which the basic patent application was lodged and the date of the first authorisation to place the product on the market, reduced by five years. Article 13 neither clearly indicates whether the rule for calculating the period of exclusivity conferred by an SPC is governed by the procedural law of the member state concerned or solely by the provision nor whether the period counts from the date of adoption or the date of notification of the marketing authorisation. Although there is only a small timespan between these two dates, the economic impact of this difference is substantial.

Read more: ECJ rules on date of first authorisation


By: Dr Teresa Schafer and Tim Clark
Piper Alderman, NSW, Australia

Partners Dr Teresa Schafer and Tim Clark look at the latest developments in this area of the patentability of genes and genetic material and explore some of the legal issues which still need to be resolved.

Read more: The Public Debate About the Patentability of Biological Material: Is It Much Ado About Nothing?


Rowedder Zimmerman Hass will host the second TAGLaw IP/IT Specialty Group meeting on September 16-18, 2011 in Mannheim, Germany. The conference will focus on the project to implement a unitary patent

Read more: Intellectual Property Specialty Group Meeting September 16-18, 2011


Following is a summary report of the IP/IT Specialty Group and the Life Sciences Specialty Group joint session on May 11, 2010, at TAGLaw's international conference in Amsterdam, submitted by Mark Thomas of Williams Mullen.

Read more: IP/IT Specialty Group and the Life Sciences Specialty Group Conference Session Summary